Australia · Delayed Price · Currency is AUD SDI Limited Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders considered and voted on a Scheme for full acquisition by a Chinese bidder, with the Board unanimously recommending approval. Key topics included the absence of dividends, virtual meeting format, and rationale for the sale. Proxy votes were disclosed and the poll results will be released to the ASX.
Fiscal Year 2025
-
The meeting reviewed stable profits and margins despite sales declines, with strong growth in aesthetic and whitening products and continued investment in R&D and ESG. Board renewal and audit tendering were discussed, and all resolutions received board support.
-
FY 2025 saw flat revenue at $110.4 million, with gross margin up 80 bps to 62.9% and EBITDA down 2.7%. European and Brazilian markets grew, while amalgam sales declined sharply. Continued automation, product innovation, and the Montrose relocation are set to drive future growth.
-
First half FY 2025 saw sales dip 1.3% to AUD 51.5 million, but gross margin rose to 63.5% and net profit after tax surged to AUD 3.8 million. Growth in Europe and Brazil offset declines elsewhere, with new products like Stela and ongoing automation investments expected to drive future gains.
Fiscal Year 2024
-
Record sales and profit were achieved, driven by strong European growth and new product launches. Strategic focus includes transitioning to Stela, expanding manufacturing, and maintaining ESG priorities. All resolutions, including director re-elections and dividend increase, were supported.
-
Record sales and profit were achieved, driven by high-margin aesthetic products and operational efficiencies. Gross margin rose to 62.1%, with EBITDA up 35.5% and NPAT up 51.8% year-over-year. Project Montrose and automation investments are set to drive future growth.